The panel, called the Advisory Committee on Immunization Practices, convened following an update from the Food and Drug Administration on the risk of rare but potentially life-threatening blood clots linked to the Johnson & Johnson vaccine.
At least 54 people in the United States, mostly women, have been hospitalized from these blood clots, and nine people have died.
The panel voted unanimously in favor of deeming the mRNA vaccines, from Pfizer and Moderna, the “preferred” options for adults over the Johnson & Johnson vaccine, ultimately concluding that the mRNA vaccines provided greater protection and fewer risks than Johnson & Johnson’s. The recommendation would not prohibit use of the Johnson & Johnson shot, but instead make clear that the other options are a better choice if they are available.
Join the conversation as a VIP Member